AGM Information • May 14, 2025
AGM Information
Open in ViewerOpens in native device viewer
Minutes from the annual general meeting 2025
The annual general meeting of Oncoinvent ASA was held today, on 14 May 2025, as a digital meeting through Microsoft Teams. All proposals on the agenda were adopted in accordance with the board of directors' proposals and the proposals from the nomination committee.
The minutes of the annual general meeting are attached hereto and are also available on the company's website www.oncoinvent.com/investors/general-meetings.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: [email protected]
Tore Kvam, Chief Financial Officer
Email: [email protected]
About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers. The technology platform is focused on the use of alphaemitting radionuclides to deliver powerful radiation directly to cancer cells. The Company’s lead product candidate, Radspherin®, is being advanced through clinical development by a team with experience from all stages of radiopharmaceutical development. Internal manufacturing and supply chain capabilities have been established, which now have the capacity to supply Radspherin® for multi-center phase 2 clinical studies.
This information is subject to disclosure under the Norwegian Securities Trading Act section 5-12 and the requirements of Oslo Børs' Continuing Obligations.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.